Obesity and age do not appear to influence the survival of patients with non-small cell lung cancer (NSCLC) treated with programmed death receptor-1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICI), according to an analysis presented at the IASLC 2019 World Conference on Lung Cancer.
To better understand how age and body mass index (BMI) affect clinical response in patients treated with ICI therapy, researchers conducted a retrospective analysis of patients with advanced NSCLC (N=381) from 3 institutions (Dijon Cancer Center, University of Montreal University Hospital and Quebec Heart and Lung Institute). Baseline characteristics included a median BMI of 24.5 (range 16.2-43.4), with 32.7% of patients being overweight and 13.6% obese. The median age was 66 (range 37-89); 29% of patients were over the age of 70.
Results from the analysis showed that BMI and age, when considered as continuous or categorical variables, did not influence progression-free survival (PFS) and overall survival (OS) outcomes in the ICI patient population, with the exception of BMI in the Dijon cohort (continuous: hazard ratio [HR] 0.95, 95% CI [0.91-0.99]; <25 vs >25: HR 0.68, 95% CI [0.47-0.99]). Additionally, no significant effect on outcomes was noted in the subgroup analysis and multivariate cox regression model. Toxicity was reported to be comparable between the groups.
“Unlike previously described in the era of chemotherapy, obesity and age were not associated with outcomes in NSCLC patients treated with ICI,” the authors concluded.
For more information visit iaslc.org.
Richard C, Elkrief A, Malo J, et al. Body mass index and age do not influence survival in patients with lung cancers treated with PD1/PDL1 immune checkpoint inhibitors. Presented at: The IASLC 2019 World Conference on Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer; September 7-10, 2019; Barcelona Spain. Abstract P1.04-01.
This article originally appeared on MPR